{"Title":"Nightstar Therapeutics Ltd.","Industry":"BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES","Employees":"23","Founded":"","Address":"","Phone":"+44 20 7611 2077","Web_address":"http://www.nightstartx.com","Market_cup":"$393.4mil","Revenues":"$0 mil (last 12 months)","Net_income":"$-12.9 mil (last 12 months)","Symbol":"NITE","Exchange":"NASDAQ","Shares":"5.4","Price_range":"$14.00 - $14.00","Est_volume":"$75.0 mil","Manager":"Jefferies/ Leerink Partners/ BMO Capital Markets","CO_managers":"Wedbush PacGrow/ Chardan","Exp_to_trade":"9/28/2017","Status":"","Quiet_period":"Available only to Subscribers","Lock_up_period":"Available only to Subscribers","Scoop_rate":"Available only to Subscribers","Rating_change":"Available only to Subscribers","Business":"We are a leading clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. Leveraging our expertise in ophthalmology, gene therapy and drug development, we are developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases for which there are no currently approved treatments."}